Trends in Patient Access to and Utilization of Prescribed PCSK9 Inhibitors in a Large US Claims Database From 2015 to 2021

Circ Cardiovasc Qual Outcomes. 2024 Feb;17(2):e009988. doi: 10.1161/CIRCOUTCOMES.123.009988. Epub 2024 Feb 16.

Authors

Diane E MacDougall¹, Seth J Baum^{1

2}, Catherine D Ahmed¹, Mary P McGowan^{1

3}, Katherine A Wilemon¹

Affiliations

¹ Family Heart Foundation, Fernandina Beach, FL (D.E.M., S.J.B., C.D.A., M.P.M., K.A.W.).
² Flourish Research, New York, NY (S.J.B.).
³ Dartmouth-Hitchcock Medical Center, Lebanon, NH (M.P.M.).

No abstract available

Keywords: PCSK9 inhibitors; cardiovascular diseases; hypercholesterolemia; prescriptions.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anticholesteremic Agents* / adverse effects
Humans
Hypercholesterolemia*
PCSK9 Inhibitors
Proprotein Convertase 9

Substances

PCSK9 Inhibitors
PCSK9 protein, human
Proprotein Convertase 9
Anticholesteremic Agents